EP2134397B1 - High frequency oscillation respiratory therapy device - Google Patents

High frequency oscillation respiratory therapy device Download PDF

Info

Publication number
EP2134397B1
EP2134397B1 EP08744956.7A EP08744956A EP2134397B1 EP 2134397 B1 EP2134397 B1 EP 2134397B1 EP 08744956 A EP08744956 A EP 08744956A EP 2134397 B1 EP2134397 B1 EP 2134397B1
Authority
EP
European Patent Office
Prior art keywords
port
flow
gas flow
primary passageway
entrainment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP08744956.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2134397A1 (en
EP2134397A4 (en
Inventor
Thomas J. Dunsmore
Thomas C. Wilschke
Geoffrey C. Wise
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CareFusion Corp
Original Assignee
CareFusion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39808728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2134397(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CareFusion Corp filed Critical CareFusion Corp
Publication of EP2134397A1 publication Critical patent/EP2134397A1/en
Publication of EP2134397A4 publication Critical patent/EP2134397A4/en
Application granted granted Critical
Publication of EP2134397B1 publication Critical patent/EP2134397B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0096—High frequency jet ventilation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M16/0006—Accessories therefor, e.g. sensors, vibrators, negative pressure with means for creating vibrations in patients' airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A61M16/122—Preparation of respiratory gases or vapours by mixing different gases with dilution
    • A61M16/125—Diluting primary gas with ambient air
    • A61M16/127—Diluting primary gas with ambient air by Venturi effect, i.e. entrainment mixers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A61M16/16—Devices to humidify the respiration air
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A61M16/208—Non-controlled one-way valves, e.g. exhalation, check, pop-off non-rebreathing valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0208—Oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/14—Static flow deviators in tubes disturbing laminar flow in tubes, e.g. archimedes screws

Definitions

  • the present invention is defined in independent claim 1 and relates to respiratory therapy devices. More particularly, it relates to percussive respiratory devices that deliver high frequency pulses of air to a patient during the patient's inspiratory and expiratory cycles.
  • PAP positive airway pressure
  • HFO high frequency oscillation
  • HFO reduces the viscosity of sputum in vitro, which in turn has a positive effect on clearance induced by an in vitro simulated cough.
  • HFO can be delivered or created via a force applied to the patient's chest wall (i.e., chest physical therapy (CPT), such as an electrically driven pad that vibrates against the patient's chest), or by applying forces directly to the patient's airway (i.e., breathing treatment, such as high frequency airway oscillation).
  • CPT chest physical therapy
  • breathing treatment such as high frequency airway oscillation
  • Many patients and caregivers prefer the breathing treatment approach as it is less obtrusive and more easily administered.
  • PAP bronchial hygiene techniques have emerged as an effective alternative to CPT for expanding the lungs and mobilizing secretions.
  • an BPV system includes a hand-held device establishing a patient breathing circuit to which a source of positive pressure gas (e.g., air, oxygen, etc.), is fluidly connected.
  • a source of positive pressure gas e.g., air, oxygen, etc.
  • the pressure source and/or the device further include appropriate mechanisms (e.g., control valves provided as part of a driver unit apart from the hand-held device) that effectuate intermittent flow of gas into the patient breathing circuit, and thus percussive ventilation of the patient's lungs.
  • each percussive cycle can be programmed by the patient or caregiver with certain systems, and can be used throughout both inspiratory and expiratory phases of the breathing cycle.
  • IPV devices include D?V(R) ventilator device (from PercussionAire Corp.
  • U.S. Patent No. 7,191,780 describes an IPV-type treatment apparatus, connectable to a source of pressurized gas, that requires a shrouded, fixed venturi tube for delivering the desired therapy.
  • US Patent No. 6595203 describes a unitary breathing head device for administering intermittent percussive ventilation to a patient having an airway and for use with an IPV device having a source of continuous gas flow and having a source of pulsed gases.
  • the device comprises a combination injector and exhalation valve assembly comprising a main body having an airway port for communication with the airway of the patient and having proximal and distal extremities and a flow passage extending from the proximal extremity to the distal extremity.
  • the main body has a depending portion forming a plenum chamber in communication with the flow passage in the main body.
  • a nebulizer is removably secured to the depending portion of the main body and has a nebulizer chamber in communication with the plenum chamber.
  • the depending portion of the main body and the nebulizer form a handle adapted to be gripped by the hand of the patient holding the breathing head assembly.
  • US Patent application no. 2006/213507 describes a nebulizer for delivering aerosolized fluid to an inhaling patient.
  • the nebulizer includes a fluid channel air inlet and fluid channel air inlet valve responsive to either a manual force external of the nebulizer, or a patient's breathing, to begin the nebulization process.
  • a method of providing nebulization including the steps of moving a fluid channel air inlet valve against a fluid channel air inlet so that a negative pressure may build up over the fluid in the fluid channel to draw fluid from the fluid reservoir and begin nebulization during inhalation.
  • European patent application no. 1516640 describes a continuous high-frequency oscillation breathing device to deliver therapy during both inhalation and exhalation in order to assist in clearing secretions from the lungs.
  • a fixed shrouded-venturi patient interface circuit is combined with medicated aerosol to deliver continuous high-frequency oscillation therapy.
  • Fixed open apertures in the patient interface circuit allow ingress and egress of flow, and are calibrated to allow exhalation and prevent stacking of successive breaths.
  • German patent application no. DE19505409 describes a breathing therapy apparatus for generating breathable gas pulses.
  • An electromotor, eccentric disc, drive belt, piston rod, piston, cylinder, suction valve and outlet valve are connected to a patient coupling which consists of an injector and mouthpiece.
  • a solenoid or drawing magnet with a regulator for the lifting and pulling frequency can be used.
  • An external motor can be coupled to the apparatus through a flexible shaft.
  • a respiratory therapy device including a housing, a flow diverter structure, a pressure port (e.g. a HF port), and an entrainment port.
  • the housing defines a primary passageway having a patient interface side.
  • the flow diverter structure is maintained by the housing in fluid communication with the primary passageway opposite the patient interface side.
  • the flow diverter structure is characterized by the absence of a venturi tube.
  • the pressure port is maintained by the housing and is configured for fluid connection to a source of oscillatory gas flow. Further, the pressure port is fluidly associated with the flow diverter structure.
  • the entrainment port is also maintained by the housing, is openable to ambient air, and is fluidly associated with the flow diverter structure.
  • the device is configured such that flow characteristics of gas flow via the pressure port from an external source are altered upon interacting with the flow diverter structure to create a pressure drop for drawing in ambient air through the entrainment port in delivering a percussive pressure therapy to the patient side of the primary passageway.
  • the flow diverter structure comprises a neck region having a tapering portion that tapers in cross-section toward the primary passageway and a diverter body disposed within the tapering portion, the diverter body having a shape that tapers toward the primary passageway.
  • the pressure port is connected to or forms a nozzle having a nozzle end that faces the flow diverter structure, with the neck region forming a reduced-size passage immediately adjacent the primary passageway.
  • the device further includes a continuous positive pressure port (CPP port) configured for fluid connection to a source of continuous positive pressure gas flow.
  • CPP port continuous positive pressure port
  • the flow diverter structure moves in response to pressure pulses delivered via the HF port in affecting gas flow from the CPP port toward the primary passageway.
  • the CPP port can be the same port as the HF port in some constructions.
  • a respiratory therapy system including a source of oscillatory gas flow and a respiratory therapy device.
  • the respiratory therapy device includes the housing, flow diverter structure, HF port, and entrainment port as described above.
  • the source of oscillatory gas flow is fluidly connected to the HF port.
  • oscillatory gas flow from the source is delivered to the respiratory therapy device and impacted by the flow diverter structure to cause entrainment of ambient air with the pressure pulses delivered to the patient interface side, and thus the patient.
  • a respiratory therapy device including a housing, a continuous positive pressure port (CPP port), a flow diverter structure, a high frequency pressure port (HF port), and an entrainment port.
  • the housing defines a primary passageway having a patient interface side.
  • the CPP port is maintained by the housing and is configured for fluid connection to a source of continuous positive pressure gas flow.
  • the flow diverter structure includes an obstruction body movably maintained within the housing, fluidly between the CPP port and the primary passageway.
  • the HF port is also maintained by the housing and is fluidly connected to the flow diverter structure.
  • the HF port is configured for fluid connection to a source of oscillatory gas flow such that a pressure pulse delivered to the HF port causes movement of the obstruction body.
  • the entrainment port is maintained by the housing and is openable to ambient air, with the entrainment port being fluidly associated with the flow diverter structure.
  • the device is configured such that flow characteristics of gas flow from the CPP port are selectively altered upon interaction with the obstruction body to deliver a percussive pressure therapy to the patient interface side of the primary passageway.
  • the obstruction body is longitudinally movable relative to a central axis of the CPP port. In other embodiments, the obstruction body is rotatably mounted within the housing.
  • the respiratory therapy device 20 operates to deliver high frequency pulses of air to a patient during the patient's inspiratory and expiratory cycles when connected to a source of oscillatory gas flow 22.
  • the source of oscillatory gas flow 22 can assume a variety of forms known in the art, and generally includes a flow interrupter valve or similar structure capable of generating an oscillatory flow of positive pressure gas (e.g., air, oxygen, etc.), such as that described in U.S. Patent No. 4, 805, 613 .
  • positive pressure gas e.g., air, oxygen, etc.
  • the therapy device 20 can be configured to establish an oscillatory flow when acting upon a constant flow of gas such that the source 22 can be a source of constant gas flow.
  • the respiratory therapy device 20 includes a housing 24 maintaining and/or forming various components such as a high frequency flow port (HF port) 26, one or more entrainment ports 28, a flow diverter structure 30, one or more exhaust apertures 32, and a mouthpiece 34.
  • the respiratory therapy device 20 can optionally include a constant positive pressure port (CPP port) 36 and/or a nebulizer port 38.
  • CCPP port constant positive pressure port
  • the flow diverter structure 30 in accordance with the present disclosure can assume a variety of forms as described below, and in some embodiments is generally characterized as not being or including a venturi tube (fixed or sliding), where a "venturi tube” is defined to be a body including a gradually decreasing or converging diameter nozzle section that extends to a throat, followed by a gradually increasing or expanding diameter diffuser section.
  • the flow diverter structure 30 is fluidly connected to a primary passageway formed by the housing 24, as is the mouthpiece 34.
  • the mouthpiece 34 serves as a patient interface through which the patient breathes and can assume a variety of forms.
  • the primary passageway of the housing 24 can be defined as having a patient interface side 40 at which the mouthpiece 34 is connected.
  • high frequency oscillatory gas flow is directed from the source 22 to the HF port 26 and then toward the flow diverter structure 30 (represented by arrows in FIG. 1 ).
  • High velocity flow from the HF port 26 e.g., a nozzle
  • the flow diverter structure 30 operates to affect gas flow from the HF port 24 in a pulse-like manner, creating a percussive gas flow/pressure effect toward the mouthpiece 34.
  • a constant input pressure flow to the housing 24 can be used, thus eliminating a need for the source of oscillatory gas flow 22.
  • the flow diverter 30 operates in response to delivered oscillatory gas flow, in turn acting upon a separate, constant flow of gas to generate oscillatory pressure pulses that are delivered to the mouthpiece 34/patient. Regardless, oscillatory pressure pulses (including entrained ambient air) are delivered to the patient via the mouthpiece 34. Between pulses, the exhaust aperture(s) 32 and the entrainment port(s) 28 allow the patient to breathe in and out of the device 20 without significant resistance.
  • the CPP port 36 can be connected to a source of positive pressure gas (not shown) to enhance the respiratory therapy provided by the device 20 (e.g., generate appropriate positive expiratory pressure (PEP), etc.), provide a primary gas flow that is acted upon by the flow diverter 30, and/or to provide other therapies (e.g., constant positive airway pressure (CPAP)).
  • a source of positive pressure gas not shown
  • PEP positive expiratory pressure
  • CPAP constant positive airway pressure
  • the optional nebulizer port 38 can be connected to a nebulizer (not shown) to introduce aerosolized medication into the gas flow delivered to the patient.
  • the nebulizer port 38 is physically positioned between the flow diverter structure 30 and the mouthpiece 34 such that the aerosolized airflow does not directly interact with the flow diverter structure 30 in a manner that might otherwise result in undesirable aerosol "knock-down".
  • FIG. 2 schematically illustrates one embodiment of a respiratory therapy device 50 in accordance with principles of the present disclosure.
  • the device 50 includes a housing 52 maintaining or connectable to a mouthpiece 54 (referenced generally) adapted for placement in a patient's mouth and through which the patient can breathe.
  • the housing 52 further forms a primary passageway 56 through which gas flow from a flow diverter structure 58 is fluidly directed to the mouthpiece 54.
  • the housing 52 further includes or forms an HF port 60, a CPP port 62, and one or more entrainment ports 64. Gas flow through the ports 60-64 is directed to the flow diverter structure 58.
  • the device 50 optionally includes one or more exhaust apertures 66 and/or a nebulizer port 68.
  • the exhaust aperture 66 and the nebulizer port 68 can be combined and/or provided as part of a singular structure that may include one or more additional valves.
  • the flow diverter structure 58 includes, in some embodiments, a neck region 70 formed in or by the housing 52.
  • the neck region 70 defines a reduced-size passage 72, and fluidly connects the primary passageway 56 with a chamber 74. More particularly, the reduced-size passage 72 has a smaller cross-sectional area (e.g., diameter) as compared to that of the chamber 74 and the primary passageway 56.
  • the reduced-size passage 72 is defined by an inlet side 76 and an outlet side 78. As shown in FIG. 2 , the inlet side 76 tapers in cross-sectional area (or diameter) from the chamber 74 at which the ports 60-64 are formed.
  • the outlet side 78 has a constant diameter in extension from the inlet side 76 to the primary passageway 56.
  • the flow diverter structure 58 can include a diverter body 80 centrally positioned within the reduced-size passage 72, adjacent the inlet side 76.
  • the diverter body 80 includes or defines a leading end 82 and a trailing end 84, with the diverter body 80 tapering in size or diameter from the trailing end 84 to the leading end 82.
  • the diverter body 80 affects airflow from the HF port 60 and the CPP port 62 as described below. In other embodiments, the diverter body 80 can be eliminated.
  • the HF port 60 is adapted to be fluidly connected to the source of oscillatory gas flow 22 ( FIG. 1 ), for example via appropriate tubing (not shown).
  • the HF port 60 is fluidly connected to or forms an HF nozzle 86.
  • the HF nozzle 86 terminates at a nozzle end 88, and is configured to generate jet gas flow.
  • the nozzle end 88 "faces" the diverter body 80 such that jet flow from the HF port 60 (and thus from the source of oscillatory gas flow 22) impinges upon the diverter body 80.
  • the CPP port 62 is similarly constructed for fluid connection to a source of continuous or constant positive pressure gas (not shown).
  • the CPP port 62 is fluidly connected to or forms a CPP nozzle 90 terminating at a nozzle end 92.
  • the CPP nozzle 90 converts gas flow through the CPP port 62 into jet flow, with the nozzle end 92 "facing" the diverter body 80. Thus, gas flow through and from the CPP nozzle 90 impinges upon the diverter body 80.
  • the entrainment port(s) 64 is, in some embodiments, formed along the chamber 74, and allows for passage of gas into and out of the chamber 74, and thus the housing 52.
  • the entrainment port(s) 64 is fluidly associated with the flow diverter structure 58 to promote entrainment of ambient air into the gas flow otherwise generated at the flow diverter structure 58.
  • the entrainment port(s) 64 can be located at other locations relative to the housing 52.
  • the entrainment port(s) 64 can be formed or located along the neck region 70.
  • the nozzles/jets 86, 90 converge at or along the flow diverter structure 58.
  • the flow diverter structure 58 ensures that gas flow streams from the nozzles 86, 90 are directed toward the primary passageway 56 (and thus the patient) and that adequate ambient air entrainment (via the entrainment port(s) 64) is produced.
  • the exhaust aperture 66 can simply be an orifice formed in the housing 52 adjacent the mouthpiece 54, establishing an ambient opening to the primary passageway 56.
  • a valve (not shown), such as a one-way valve, can be assembled to the exhaust aperture 66, operating to selectively control gas flow to and/or from the primary passageway 56.
  • the valve can operate to only permit release of gas from the primary passageway 56 during a patient's expiratory breath.
  • the nebulizer port 68 is adapted for connection to a nebulizer (not shown), such as a high-performance entrainment nebulizer available under the trade designation Pari LC Star, although any other nebulizer arrangement capable of generating aerosolized medication can be employed.
  • a nebulizer such as a high-performance entrainment nebulizer available under the trade designation Pari LC Star, although any other nebulizer arrangement capable of generating aerosolized medication can be employed.
  • the nebulizer port 68 is formed adjacent the mouthpiece 54 (and thus "downstream" of the flow diverter structure 58). With this positioning, aerosolized entrainment within the gas flow being delivered to the mouthpiece 54/patient can occur without resulting in significant aerosol knock-down within the flow diverter structure 58.
  • a one-way valve (not shown) can be provided to ensure desired airflow from the nebulizer into the primary passageway 56.
  • FIGS. 3A and 3B Operation of the respiratory therapy device 50 is shown in the illustrations of FIGS. 3A and 3B .
  • a constant flow of positive pressure gas is delivered to the flow diverter structure 58 via the CPP nozzle 90.
  • oscillatory (i.e., pulsed) gas flow is provided to the flow diverter structure 58 via the HF nozzle 86.
  • gas flow through the HF nozzle 86 is characterized as being intermittent positive-pressure pulses, and thus has “pulse on” and “pulse off” phases. During the "pulse on” phase ( FIG.
  • gas flow from the HF nozzle 86 and the CPP nozzle 90 converge at the flow diverter structure 58, and are directed along the reduced-size passage 72 and then the primary passageway 56 (shown by arrows in FIG. 3A ). Due to the reduced area at the reduced-size passage 72 (as compared to an area of the chamber 74 and the primary passageway 56), the so-delivered gas flow increases in velocity along the reduced-size passage 72, thus drawing or entraining ambient air into the gas stream via the entrainment port(s) 64. Where the diverter body 80 ( FIG. 2 ) is provided, a further reduction in flow area, and thus increase in velocity is created. In the "pulse off' phase ( FIG.
  • gas flow to the flow diverter structure 58 is provided only by the CPP nozzle 90.
  • the flow diverter structure 58 directs the gas flow along the reduced-size passage 72 and to the primary passageway 56 such that ambient air is entrained via the entrainment port(s) 64 as described above.
  • an elevated baseline pressure is provided to the patient on a continuous basis.
  • Other respiratory therapies can also be effectuated with the device 50.
  • gas flow through the CPP nozzle 90 can be removed where high frequency oscillatory therapy without an elevated baseline pressure is desired.
  • gas flow via the HF nozzle 86 can be omitted where only constant positive airway pressure (CPAP) therapy is desired.
  • CPAP constant positive airway pressure
  • the patient breathes into and out of the therapy device 50 via the mouthpiece 54.
  • the entrainment port(s) 64 and the exhaust aperture(s) 66 (in combination with a one-way valve, in some embodiments) allows the patient to breathe into and out of the device 50 without significant resistance during at least the "pulse off' phase.
  • aerosolized medication can be introduced into the flow stream at the primary passageway 56 via the nebulizer port 68.
  • aerosolized flow is entrained into the gas flow generated in the primary passageway 56 by the flow diverter structure 58 and thus delivered to the patient via the mouthpiece 54.
  • the device 100 includes a housing 102 maintaining or forming or connectable to a mouthpiece 104 (drawn generally) through which a patient breathes.
  • the housing 102 establishes a primary passageway 106 through which airflow into and out of the mouthpiece 104 is directed.
  • HF flow into the primary passageway 106 is established via a flow diverter structure 108 formed opposite the mouthpiece 104 and fluidly associated with an HF port 110 and one or more entrainment ports 112.
  • the flow diverter structure 108 includes a plate 114 that forms an orifice 116.
  • the plate 114 is positioned or formed within the housing 102 so as to establish or define a chamber 118 opposite the primary passageway 106, with the orifice 116 fluidly connecting the passageway 106 and the chamber 118.
  • the orifice 116 has an area (i.e., diameter) that is less than that of the chamber 118 as well as the passageway 106. Further, a diameter of the orifice 116 is uniform through a thickness of the plate 114 in some configurations. Although only the single orifice 116 is shown in FIG. 4 , in other embodiments, the plate 114 can form two or more orifices.
  • the HF port 110 is associated with the chamber 118, and is configured for establishing a fluid connection with the source of oscillatory gas flow 22 ( FIG. 1 ). Further, the HF port 110 is fluidly connected to or forms a nozzle 120 terminating at a nozzle end 122. As with previous embodiments, the HF nozzle 120 is configured to establish jet flow of gas, and the nozzle end 122 is generally aligned with or "faces" the orifice 116. As shown, at least a slight gap exists between the nozzle end 122 and the plate 114/orifice 116.
  • the entrainment port(s) 112 establishes a fluid opening between the chamber 118 and ambient air. While the entrainment port(s) 112 is shown as being formed adjacent the HF port 110, any other location in fluid communication with the chamber 118 is also acceptable.
  • oscillatory gas flow is delivered to the HF port 110 and the "pulsed on" flow is directed by the nozzle end 122 toward the orifice 116.
  • a pressure drop is generated within the chamber 118 as gas flow from the nozzle end 122 passes through the orifice 116.
  • the reduced size of the orifice 116 increases the velocity of gas flowing therethrough, thus lowering the surrounding pressure to generate the pressure drop.
  • the pressure drop draws and entrains ambient air into the gas stream via the entrainment port(s) 112.
  • a substantial volume of high frequency pulsed gas flow is delivered to the primary passageway 106, and thus the mouthpiece 104/patient.
  • the device 100 can further include one or more exhaust apertures 124. Between pulses of the high frequency oscillating gas flow being generating within the primary passageway 106, the exhaust aperture(s) 124 and the entrainment port(s) 112 allow the patient to breathe into and out of the device 100 without significant resistance.
  • a valve structure (not shown), such as a one-way valve, can be assembled to the exhaust aperture(s) 124.
  • the respiratory therapy device 100 can include an optional nebulizer port 126 adapted for connection to a nebulizer (not shown).
  • the nebulizer port 126 is preferably located along the primary passageway 106, between the flow diverter structure 108 and the mouthpiece 104. With this position, aerosolized medication being delivered to the primary passageway 106 (and thus entrained within the gas flow being delivered to the mouthpiece 104/patient) is not required to pass through the flow diverter structure 108 (or any other structure that might otherwise result in significant aerosol knock-down).
  • a valve mechanism can be associated with the nebulizer port 126, operating to allow influx of aerosolized medication via the nebulizer port 126 during only the patient's inspiratory breath and/or between the oscillatory pulses that occur during a patient's inspiratory breath.
  • the entrainment port(s) 112 and the exhaust aperture(s) 124 can be balanced with the nebulizer valve (and/or appropriate valving can be placed on the entrainment port(s) 112 and/or the exhaust aperture(s) 124) to ensure "activation" of nebulizer entrainment during the patient's inspiratory breath and/or between the oscillatory pulses that occur during a patient's inspiratory breath.
  • FIG. 5 Yet another embodiment of a respiratory therapy device 140 is shown in FIG. 5 .
  • the device 140 includes a housing 142 maintaining or forming or connectable to a mouthpiece 144 (drawn generally) through which a patient can breathe.
  • the housing 142 forms a primary passageway 146 through which gas flow to and from the mouthpiece 144 is established.
  • a flow diverter structure 148 (referenced generally) is fluidly connected to the primary passageway 146 opposite the mouthpiece 144, with gas flow being directed to the flow diverter structure 148 via an HF port 150.
  • the housing 142 forms or includes one or more entrainment ports 152 through which ambient air is drawn into and entrained with the flow stream generated at the flow diverter structure 148.
  • the flow diverter structure 148 separates the primary passageway 146 from a chamber 154, and includes a ring orifice 156 and a neck region 158.
  • the ring orifice 156 is fluidly connected to the HF port 150, and establishes an encircling opening 160 to the chamber 154.
  • gas flow from the HF port 150 is directed into the chamber 154 via the ring orifice 156.
  • the neck region 158 includes an inlet portion 162 and a reduced-size passage 164.
  • the inlet portion 162 has a tapering diameter in extension from the chamber 154 (and more particularly, the opening 160 of the ring orifice 156) to the reduced-size passage 164. As described below, this relationship promotes formation of a Coanda effect upon gas flow exiting the ring orifice 156.
  • the reduced-size passage 164 has a uniform diameter in extension from the inlet portion 162 to the primary passageway 146, with a diameter of the reduced-size passage 164 being less than that of the chamber 154 and the primary passageway 146 such that gas flow experiences an increase in velocity when directed from the chamber 154 to the primary passageway 146.
  • the HF port 150 is configured for fluid attachment to the source of oscillatory gas flow 22 ( FIG. 1 ), and is fluidly open to the ring orifice 156 as described above.
  • the entrainment port(s) 152 can be positioned at a "back" of the chamber 154, or can be spatially closer to the flow diverter structure 148.
  • oscillatory gas flow is provided to the ring orifice 156 via the HF port.
  • a Coanda effect is created, causing the flow to "attach" to the inlet portion 162 and be forced toward the reduced-size passage 164.
  • flow velocity increases (due to the reduced area or diameter of the passage 164 as compared to the chamber 154), generating a pressure drop in the chamber 154.
  • the pressure drop draws ambient air through the entrainment port 152.
  • significant entrainment of ambient air into the gas flow delivered to the primary passageway 146 occurs.
  • the gas flow delivered to the primary passageway 146 has oscillating pressure characteristics reflected in FIG. 5 by waves.
  • the respiratory therapy device 140 can further include an optional exhaust aperture 170 that fluidly connects the primary passageway 146 with ambient.
  • an optional valving structure (not shown) can be assembled to the exhaust aperture 170.
  • the respiratory therapy device 140 can further include an optional nebulizer port 172 adapted for fluid connection to a nebulizer (not shown) as previously described.
  • the nebulizer port 172 is fluidly open to the primary passageway 146, and can be positioned or formed between the mouthpiece 144 and the flow diverter structure 148 so as to minimize interaction between the aerosolized medication and the flow diverter structure 148.
  • the nebulizer port 172 provides a conduit through which aerosolized medication can be entrained into the gas flow being delivered to the patient via the mouthpiece 144.
  • additional valving structures can be associated with the nebulizer port 172 to enhance efficiency of aerosol delivery.
  • the entrainment port(s) 152 and the exhaust aperture 170 can be balanced with the nebulizer entrainment valve (or other valving) to ensure that nebulizer entrainment is "activated" during the patient's inspiratory breath and between the oscillatory pulses that occur during a patient's inspiratory breath.
  • FIGS. 6A and 6B Another embodiment of a respiratory therapy device 200 in accordance with aspects of the present disclosure is shown in FIGS. 6A and 6B .
  • the device 200 again includes a housing 202 forming or maintaining or connectable to a mouthpiece 204 (illustrated generally) through which a patient breathes.
  • gas flow to and from the mouthpiece 204 is provided via a primary passageway 206 defined by the housing 202.
  • a flow diverter structure 208 is fluidly connected to the primary passageway 206 opposite the mouthpiece 204, the flow diverter structure 208 separating the primary passageway 206 from a chamber 209.
  • the flow diverter structure 208 operates in response to gas flow at an HF port 210 to affect gas flow directed to the chamber 209/flow diverter structure 208 via a CPP port 212.
  • the housing 202 forms or includes one or more entrainment ports 214 through which ambient air is drawn into and entrained with the flow stream generated at the flow diverter structure 208.
  • the housing 202 optionally forms or includes one or more exhaust apertures 216 and/or a nebulizer port 218.
  • the nebulizer port 218, where provided, can be positioned adjacent the mouthpiece 204 and thus fluidly "downstream" of the flow diverter structure 208 to minimize aerosol knock-down.
  • the flow diverter structure 208 includes a baffle device 220 slidably maintained within the housing 202.
  • the baffle device 220 includes or forms an obstruction body 222 fluidly associated with the CPP port 212. More particularly, the baffle device 220 operates to move the obstruction body 222 toward and away from the CPP port 212, thus altering the level of gas flow entering the primary passageway 206 from the chamber 209/CPP port 212, as well as the volume of ambient air entrained therein via the entrainment port(s) 214.
  • the obstruction body 222 can have a variety of different geometries selected to affect gas flow from the CPP port 212 as desired.
  • the conical shape accorded to the obstruction body 222 in FIGS. 6A and 6B is but one, non-limiting example.
  • the baffle device 220 can be configured in a variety of fashions to provide the above-described movement.
  • the baffle device 220 includes an annular hub 224 having a leading end 226 and a trailing end 228.
  • a radial support 230 extends from the leading end 226 and maintains the obstruction body 222 relative to the hub 224.
  • the support 230 forms channels 231 through which gas flow can occur.
  • the hub 224 is slidably disposed within an annular slot 232 formed by the housing 202, for example by a shoulder 234.
  • the slot 232 is fluidly connected to the HF port 210 and is sized to establish a fluidly-sealed relationship relative to the hub 224.
  • a biasing member 236 biases the hub 224 to the closed position, with the shoulder 234 providing a stop surface to movement of the hub 224 beyond the closed position of FIG. 6A (i.e., the shoulder prevents the hub 224 from moving leftward in FIG. 6A ).
  • a pressure pulse imparted into the slot 232 acts upon the hub 224, generating a sufficient force to overcome that of the biasing member 236, causing the hub 224 to move within the slot 232 (rightward relative to the orientation of FIG. 6A ).
  • This movement is translated onto the obstruction body 222 via the support 230.
  • the baffle device 220 in response to a positive pressure pulse within the slot 232 via the HF port 210, the baffle device 220 "moves" such that the obstruction body 222 is positioned away from the CPP port 212 as shown in the opened state of FIG. 6B .
  • the biasing member 236 forces the hub 224, and thus the obstruction body 222, to return to the normal, closed position ( FIG. 6A ).
  • the HF port 210 can be eliminated.
  • the CPP port 212 is adapted for connection to a source of constant positive pressure gas, for example via tubing (not shown), and is fluidly connected to and/or forms a CPP nozzle 238.
  • the CPP nozzle 238 generates jet flow, exiting at a nozzle end 240 that is otherwise fluidly associated or aligned with the obstruction body 222.
  • the entrainment port(s) 214 are open to ambient, and are fluidly associated with the nozzle end 240 of the CPP nozzle 238 at or "upstream" of the obstruction body 222. More particularly, the entrainment port(s) 214 is positioned such that high velocity gas flow generated at the nozzle end 240 causes ambient air to be drawn or entrained into the flow stream as described below.
  • the exhaust aperture(s) 216 is similar to the exhaust aperture 66 ( FIG. 2 ) previously described, and may or may not be associated with a valve (not shown). Regardless, the exhaust aperture(s) 216 facilitates patient breathing into and out of the device 200 by providing an ambient opening to the primary passageway 206.
  • the optional nebulizer port 218 is adapted for fluid connection to a nebulizer ((not shown) but akin to the nebulizer previously described). Where provided, the nebulizer port 218 is preferably positioned such that aerosolized airflow into the primary passageway 206 does not directly impinge upon the flow diverter structure 208. In other words, the nebulizer port 218 is located along the primary passageway 206, fluidly between the mouthpiece 204 and the obstruction body 222, thus minimizing prevalence of aerosol knock-down. Alternatively, the nebulizer port 218 can be located at virtually any other location along the housing 202, and in other embodiments can be eliminated.
  • the flow diverter structure 208 operates to selectively alter the volume of gas flow from the CPP port 212 to the primary passageway 206.
  • a jet flow of gas is delivered to the chamber 209 and impinges upon the obstruction body 222.
  • Gas flow interfaces with the obstruction body 222 and flows through the channels 231, creating a vacuum effect, drawing in, or entraining, a significant level of ambient air (via the entrainment port(s) 214).
  • the baffle device 220 can be configured to provide a known gap 242 in the engaged state ( FIG. 6A ) to achieve a desired minimum baseline pressure profile. Regardless, between pulses, the entrainment port(s) 214 and the exhaust aperture(s) 216 effectively allow the patient to breathe in and out of the device 200 without significant resistance.
  • aerosolized medication can be introduced into the gas flow being directed toward the patient via the nebulizer port 218.
  • the entrainment port(s) 214 and the exhaust aperture(s) 216 can be dimensionally balanced with valving (not shown) associated with the nebulizer port 218 ensuring that nebulizer entrainment is "activated" during the patient's inspiratory breath and between the oscillatory pulses that occur during a patient's inspiratory breath.
  • FIGS. 7A and 7B Another embodiment of a respiratory therapy device 300 in accordance with aspects of the present disclosure is shown in FIGS. 7A and 7B .
  • the device 300 includes a housing 302 forming, maintaining, or connectable to a mouthpiece 304 (illustrated generally) through which a patient breaths. Gas flow to and from the mouthpiece 304 is provided via a primary passageway 306 defined by the housing 302.
  • a flow diverter structure 308 is fluidly connected to the primary passageway 306 opposite the mouthpiece 304, and acts upon gas flow directed into a chamber 309 of the housing 308 via a CPP port 310.
  • the flow diverter structure 308 is fluidly connected to an HF port 312 through which an oscillatory pressure serves to actuate the flow diverter structure 308 as described below.
  • the housing 302 forms or includes one or more entrainment ports 314 through which ambient air is drawn into and entrained within the flow stream generated at the diverter structure 308.
  • the housing 302 optionally forms or includes one or more exhaust apertures 316 and/or a nebulizer port 318.
  • the nebulizer port 318 can be positioned adjacent the mouthpiece 304 and thus fluidly "downstream" of the flow diverter structure 308 to minimize aerosol knock-down.
  • the flow diverter structure 308 includes a drive assembly 320 and obstruction bodies 322a, 322b.
  • the drive assembly 320 is slidably maintained within the housing 302, and operate to maneuver the obstruction bodies 322a, 322b between an opened position ( FIG. 7A ) and a closed position ( FIG. 7B ).
  • the obstruction bodies 322a, 322b are fluidly associated with the chamber 309/CPP port 310, and operate to alter the level of gas flow entering the primary passageway 306 from the chamber 309/CPP port 310, as well as the volume of ambient air entrained therein via the entrainment ports 314.
  • the drive assembly 320 includes an annular hub 324 having a leading end 326 and a trailing end 328.
  • a toothed inner surface 330 is formed adjacent the leading end 326, and a recess 332 is formed between the toothed surface 330 and the trailing end 328.
  • the hub 324 is sized to be slidably received within a slot 334 formed by the housing 302, for example via an annular shoulder 336.
  • at least the trailing end 328 and the slot 334 are sized so as to establish a fluidly sealed relationship.
  • the drive assembly 320 includes a biasing device 337 (e.g., a spring) positioned to bear against the leading end 326, biasing the hub 324 to the closed position of FIG. 7B .
  • a biasing device 337 e.g., a spring
  • each of the obstruction bodies 322a, 322b includes a valve plate 338 and a drive segment 340.
  • the drive segment 340 is pivotably or rotatably mounted within the housing 302 (e.g., via a pin 342), and forms a geared end 344.
  • the geared end 344 is configured in accordance with the toothed surface 330 of the hub 324 such that when the hub 324 positions the toothed surface 330 adjacent the geared ends 344, the corresponding teeth mesh with one another and movement of the hub 324 is transferred to the drive segment 340, thereby causing movement of the corresponding obstruction body 322a, 322b.
  • the flow diverter structure 308 includes one or more components that operate to selectively hold the obstruction bodies 322a, 322b in at least the open position of FIG. 7A and/or that bias the obstruction bodies 322a, 322b to naturally assume the opened position.
  • the flow diverter structure 308 can include one or more springs (not shown) that bias the obstruction bodies 322a, 322b to the open position, with a spring force constant of this spring(s) being less than that of the biasing member 337 otherwise acting upon the hub 324 such that the biasing member 337 is capable of readily moving the hub 324 from the opened position ( FIG. 7A ) to the closed position ( FIG. 7B ) without overtly being restricted by the interface with the obstruction bodies 322a, 322b.
  • a compression spring can be disposed between the valve plate 338 of the first obstruction body 322a and the corresponding, immediately adjacent segment of the shoulder 336 that biases the valve plate 338 toward the shoulder 336 segment; a torsional spring disposed between the valve plates 338; etc.
  • the valve plates 338 can be magnetically attracted toward the corresponding shoulder 316 segment.
  • the obstruction bodies 322a, 322b can be temporarily held in a multiplicity of positions (e.g., a ball-and-detent configuration), with the corresponding holding force being less than the spring constant force associated with the biasing member 337.
  • the hub 324 Upon final assembly, the hub 324 is slidably disposed within the slot 334. Pulsed flow delivered to the slot 334 via the HF port 312 causes the hub 324 to move. In particular, a pressure pulse imparted into the slot 334 acts upon the trailing end 328 of the hub 324, generating a sufficient force to overcome that of the biasing member 337, causing the hub 324 to move within the slot, transitioning from the closed position of FIG. 7B to the opened position of FIG. 7A . This movement is translated onto the obstruction bodies 322a, 322b via the geared interface between the toothed surface 330 and the geared end 344.
  • movement of the hub 324 forces the obstruction bodies 322a, 322b to pivot about their corresponding pivot points (e.g., the pins 342), forcing the obstruction bodies 322a, 322b, and in particular the corresponding valve plates 338, toward the opened position of FIG. 7A .
  • the obstruction bodies 322a, 322b may pivot or rotate slightly with movement of the hub 324; however, upon release of the geared engagement between the toothed surface 330 and the geared end 344 (i.e., the geared end 344 of each of the obstruction bodies 322a, 322b resides within the recess 332), the obstruction bodies 322a, 322b are no longer constrained by the hub 324, and thus freely pivot to the opened position via the corresponding spring(s) (not shown).
  • the obstruction bodies 322a, 322b are in an opened position relative to the chamber 309/CPP port 310 (i.e., present minimal gas flow obstruction between the chamber 309/CPP port 310 and the primary passageway 306).
  • the biasing member 337 forces the hub 324 to return to the normal, closed position ( FIG. 7B ).
  • the hub 324 interfaces with the obstruction bodies 322a, 322b as described above, thereby actuating the hub bodies 322a, 322b to the closed position via geared engagement between the toothed surface 330 and the geared ends 344.
  • the affect of the position of the obstruction bodies 322a, 322b upon gas flow through the CPP port 310 is described below.
  • HF port 312 can be eliminated.
  • the CPP port 310 is adapted for connection to a source of constant positive pressure gas, for example via tubing (not shown), and is fluidly connected to and/or forms a CPP nozzle 350.
  • the CPP nozzle 350 generates jet flow, exiting at a nozzle end 352 that is otherwise fluidly associated or aligned with a center point 354 between the obstruction bodies 322a, 322b.
  • the entrainment port(s) 314 are open to ambient, and are fluidly associated with the nozzle end 352 of the CPP nozzle 350 at or "upstream" of the obstruction bodies 322a, 322b. More particularly, the entrainment port(s) 314 is positioned such that high velocity gas flow generated at the nozzle end 352 causes ambient air to be drawn or entrained into the flow of stream as described below.
  • the exhaust aperture(s) is similar to the exhaust aperture 66 ( FIG. 2 ) previously described, and may or may not be associated with a valve (not shown). Regardless, the exhaust aperture(s) 316 facilitates patient breathing into and out of the device 300 by providing an ambient opening to the primary passageway 306.
  • the optional nebulizer port 318 is adapted for fluid connection to a nebulizer (not shown) but akin to the nebulizer previously described. Where provided, the nebulizer port 318 is preferably positioned such that aerosolized gas flowing into the primary passageway 306 does not directly impinge upon the flow diverter structure 308. In other words, the nebulizer port 318 is located along the primary passageway 306 fluidly between the mouthpiece 304 and the obstruction bodies 322a, 322b, thus minimizing prevalence of aerosol knock-down. Alternatively, the nebulizer port 318 can be located at virtually any other location along the housing 302, and in other embodiments can be eliminated.
  • the flow diverter structure 308 operates to selectively alter the volume of gas flow from the chamber 309/CPP port 310 to the primary passageway 306.
  • a jet flow of gas is delivered from the nozzle end 352 and passes through, but at least partially impinges upon, the obstruction bodies 322a, 322b and/or the reduced diameter defined by the leading end 326 of the hub 324.
  • This interface draws in, or entrains, a significant level of ambient air via the entrainment port(s) 314.
  • aerosolized medication can be introduced into the gas flow being directed toward the patient via the nebulizer port 318.
  • the entrainment port(s) 314 and the exhaust aperture(s) 316 can be dimensionally balanced with valving (not shown) associated with the nebulizer port 318, ensuring the nebulizer entrainment is "activated" during the patient's inspiratory breath and between the oscillatory pulses that occur during a patient's inspiratory breath.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Nozzles (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Massaging Devices (AREA)
EP08744956.7A 2007-04-02 2008-04-02 High frequency oscillation respiratory therapy device Not-in-force EP2134397B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92141407P 2007-04-02 2007-04-02
PCT/US2008/059162 WO2008122045A1 (en) 2007-04-02 2008-04-02 High frequency oscillation respiratory therapy device

Publications (3)

Publication Number Publication Date
EP2134397A1 EP2134397A1 (en) 2009-12-23
EP2134397A4 EP2134397A4 (en) 2014-10-22
EP2134397B1 true EP2134397B1 (en) 2017-07-05

Family

ID=39808728

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08744956.7A Not-in-force EP2134397B1 (en) 2007-04-02 2008-04-02 High frequency oscillation respiratory therapy device

Country Status (11)

Country Link
US (1) US8528547B2 (ru)
EP (1) EP2134397B1 (ru)
JP (1) JP5390504B2 (ru)
CN (1) CN101932354B (ru)
AU (1) AU2008232449B8 (ru)
BR (1) BRPI0809602A2 (ru)
CA (1) CA2682718C (ru)
NZ (1) NZ580224A (ru)
RU (1) RU2448742C2 (ru)
WO (1) WO2008122045A1 (ru)
ZA (1) ZA200906877B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2217311B1 (en) * 2007-11-19 2017-10-18 Vyaire Medical Consumables LLC Patient interface assembly for respiratory therapy
US8539951B1 (en) 2008-05-27 2013-09-24 Trudell Medical International Oscillating positive respiratory pressure device
US8327849B2 (en) 2008-10-28 2012-12-11 Trudell Medical International Oscillating positive expiratory pressure device
US9227034B2 (en) 2009-04-02 2016-01-05 Beathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation for treating airway obstructions
US9132250B2 (en) 2009-09-03 2015-09-15 Breathe Technologies, Inc. Methods, systems and devices for non-invasive ventilation including a non-sealing ventilation interface with an entrainment port and/or pressure feature
US8485179B1 (en) 2009-02-23 2013-07-16 Trudell Medical International Oscillating positive expiratory pressure device
US9149589B2 (en) 2009-02-23 2015-10-06 Trudell Medical International Method and device for performing orientation dependent oscillating positive expiratory pressure therapy
CA2774902C (en) 2009-09-03 2017-01-03 Breathe Technologies, Inc. Methods, systems and devices for non-invasive ventilation including a non-sealing ventilation interface with an entrainment port and/or pressure feature
US10039691B2 (en) 2010-09-21 2018-08-07 Koninklijke Philips N.V. Vibratory positive expiratory pressure device
FR2971162B1 (fr) 2011-02-03 2013-11-22 Georges Boussignac Dispositif de respiration artificielle pour la reanimation d'une personne en etat d'arret cardiaque
ES2949261T3 (es) 2011-06-06 2023-09-27 Trudell Medical Int Dispositivo de presión espiratoria positiva
RU2015105382A (ru) 2012-07-18 2016-09-10 Конинклейке Филипс Н.В. Система и способ для улучшенного соблюдения режима при дыхательной терапии
US9517315B2 (en) 2012-11-30 2016-12-13 Trudell Medical International Oscillating positive expiratory pressure device
US9833584B2 (en) 2013-03-22 2017-12-05 Breathe Technologies, Inc. Portable ventilator secretion management system
US10272224B2 (en) 2013-07-12 2019-04-30 Trudell Medical International Huff cough simulation device
WO2015017416A1 (en) * 2013-07-31 2015-02-05 University Of Florida Research Foundation , Inc. High frequency airway oscillation for internal airway vibration
US9849257B2 (en) 2013-08-22 2017-12-26 Trudell Medical International Oscillating positive respiratory pressure device
US10363383B2 (en) 2014-02-07 2019-07-30 Trudell Medical International Pressure indicator for an oscillating positive expiratory pressure device
EP3191162B1 (en) * 2014-09-10 2022-02-23 Fontem Holdings 1 B.V. Methods and devices for modulating air flow in delivery devices
US10004872B1 (en) 2015-03-06 2018-06-26 D R Burton Healthcare, Llc Positive expiratory pressure device having an oscillating valve
EP4186548A1 (en) 2015-04-02 2023-05-31 Hill-Rom Services PTE. LTD. Mask leakage detection for a respiratory device
JP7016795B2 (ja) 2015-07-30 2022-02-07 トルーデル メディカル インターナショナル 呼吸筋トレーニングと呼気陽圧振動の複合装置
USD780906S1 (en) 2015-09-02 2017-03-07 Trudell Medical International Respiratory treatment device
USD778429S1 (en) 2015-09-02 2017-02-07 Trudell Medical International Respiratory treatment device
CA3005796C (en) 2015-12-04 2022-07-19 Trudell Medical International Huff cough simulation device
EP3490651B1 (en) * 2016-07-26 2021-09-01 University of Cincinnati Device comprising a fluidic diverter for assisting breathing
FI3493870T3 (fi) 2016-08-02 2023-09-11 Adel Bougatef Laite perkussiivisen ventilaatiohoidon tarjoamiseksi potilaan hengitystiehen
US20210205567A1 (en) * 2016-08-02 2021-07-08 Adel Bougatef Method and apparatus for providing percussive ventilation therapy to a patient airway
CA3059532A1 (en) 2017-05-03 2018-11-08 Trudell Medical International Combined oscillating positive expiratory pressure therapy and huff cough simulation device
US10792449B2 (en) 2017-10-03 2020-10-06 Breathe Technologies, Inc. Patient interface with integrated jet pump
US10953278B2 (en) 2018-02-02 2021-03-23 Trudell Medical International Oscillating positive expiratory pressure device
WO2019234584A1 (en) 2018-06-04 2019-12-12 Trudell Medical International Positive air pressure therapy device, kit and methods for the use and assembly thereof
CN109925575A (zh) * 2019-03-28 2019-06-25 中国人民解放军陆军特色医学中心 一种便携式气道喷雾器
SE545956C2 (en) * 2020-01-23 2024-03-26 Monivent Ab A device for a respiration arrangement providing a flow constriction with a laminar flow section comprising a plurality of elongated channels
SE544750C2 (en) * 2020-01-23 2022-11-01 Monivent Ab Device for a respiration arrangement comprising a pressure connecting portion and a flow guiding element with a shielding portion
EP4125772A1 (en) * 2020-03-23 2023-02-08 Khwaja, Kosar Ventilator adaptors
US11957838B2 (en) * 2020-07-27 2024-04-16 Pratt & Whitney Canada Corp. Patient ventilator, method of ventilating an airway of a patient, and associated computer program product

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US700610A (en) * 1901-06-27 1902-05-20 George F Bell Temper-screw.
DE661244C (de) 1934-10-15 1938-06-14 Peter Petersen Vorrichtung zur Erzeugung kuenstlicher Atmung
US2918917A (en) 1955-03-02 1959-12-29 John H Emerson Apparatus for vibrating portions of a patient's airway
US3068856A (en) 1958-02-14 1962-12-18 Forrest M Bird Fluid control device
US3191596A (en) 1960-09-19 1965-06-29 Forrest M Bird Respirator
US3234932A (en) 1960-09-19 1966-02-15 Forrest M Bird Respirator
US3301255A (en) 1963-10-18 1967-01-31 Harris A Thompson Method and apparatus for application of nebulized medication in positive pressure respiratory equipment
GB1138274A (en) 1966-03-04 1968-12-27 Liston Fletcher Inc Therapeutic respirator
US3581742A (en) 1968-06-11 1971-06-01 Medical Services Inc Intermittent positive pressure breathing device
US3580249A (en) 1968-09-16 1971-05-25 Kentaro Takaoka Aerosol nebulizers
US3610237A (en) 1968-10-07 1971-10-05 Michigan Instr Inc Inhalation positive pressure breathing apparatus
US3584621A (en) 1968-10-31 1971-06-15 Bird F M Respiratory apparatus
US3581249A (en) * 1969-01-27 1971-05-25 Gen Electric Miniature helical resonators
US3630196A (en) * 1969-08-22 1971-12-28 Bird F M Manual positive pressure breathing device
US3737448A (en) * 1970-04-01 1973-06-05 Merck & Co Inc Spiro(3.3)heptane amino acids
US3664337A (en) 1970-04-15 1972-05-23 Bio Logics Inc Respiration assembly and methods
US3653379A (en) * 1970-08-20 1972-04-04 Joseph G Glenn Adjustable pressure ippb ventilator
FR2174782B1 (ru) 1972-03-10 1975-03-21 Lafourcade Jean Michel
US3769973A (en) 1972-07-24 1973-11-06 A Esbenshade Intermittent positive pressure breathing apparatus
US3903884A (en) 1973-08-15 1975-09-09 Becton Dickinson Co Manifold nebulizer system
FR2344278A1 (fr) 1976-03-19 1977-10-14 Air Liquide Respirateur
US4323064A (en) 1976-10-26 1982-04-06 Puritan-Bennett Corporation Volume ventilator
US4231973A (en) 1978-09-29 1980-11-04 C. R. Bard, Inc. Nebulizer with variable flow rate control and associated method
US4351329A (en) 1980-11-06 1982-09-28 Bear Medical Systems, Inc. High frequency breath pump
US4592349A (en) 1981-08-10 1986-06-03 Bird F M Ventilator having an oscillatory inspiratory phase and method
US5007420A (en) 1981-08-10 1991-04-16 Bird F M Ventilator having an oscillatory inspiratory phase and method
US5116088A (en) 1981-08-10 1992-05-26 Bird F M Ventilator having an oscillatory inspiratory phase and method
US4471773A (en) * 1981-11-19 1984-09-18 Bunnell Life System, Inc. Apparatus and method for delivering medication to patient's respiratory system
US4719910A (en) 1985-04-29 1988-01-19 Jensen Robert L Oscillating ventilator and method
US4805612A (en) 1985-09-13 1989-02-21 Sensormedics Corporation High frequency ventilation
US4805613A (en) 1986-05-23 1989-02-21 Bird F M Ventilator which can be readily transported for emergency situations
US4838260A (en) 1986-05-23 1989-06-13 Bird F M Ventilator
US4930501A (en) 1986-05-23 1990-06-05 Bird F M Ventilator
US4823828A (en) 1987-05-28 1989-04-25 Mcginnis Gerald E Pressure relief valve
US5107831A (en) 1989-06-19 1992-04-28 Bear Medical Systems, Inc. Ventilator control system using sensed inspiratory flow rate
BE1004384A3 (nl) * 1989-08-03 1992-11-10 Labaere Emmanuel Toestel voor het toepassen van in- en uitademingstechnieken.
US5253641A (en) 1989-12-01 1993-10-19 Choate Thomas V Respiratory filter apparatus and method
US5345930A (en) 1992-02-10 1994-09-13 National Research Council Canada Intellectual Property Services Office Method and apparatus for assisting expulsional movement of pulmonary secretions via supramaximal flows
US5655520A (en) 1993-08-23 1997-08-12 Howe; Harvey James Flexible valve for administering constant flow rates of medicine from a nebulizer
US5570682A (en) 1993-12-14 1996-11-05 Ethex International, Inc. Passive inspiratory nebulizer system
US5479920A (en) 1994-03-01 1996-01-02 Vortran Medical Technology, Inc. Breath actuated medicinal aerosol delivery apparatus
US5598839A (en) 1994-04-20 1997-02-04 Diemolding Corporation Positive expiratory pressure device
US5613489A (en) 1994-12-07 1997-03-25 Westmed, Inc. Patient respiratory system drug applicator
WO1996024407A1 (en) * 1995-02-10 1996-08-15 Hougen Everett D A portable, personal breathing apparatus
DE19505409C2 (de) 1995-02-17 1999-11-18 Norbert Josef Rapp Atemtherapiegerät
US5823179A (en) * 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
JP3835852B2 (ja) 1996-04-19 2006-10-18 日本化薬株式会社 分散染料組成物およびそれを用いる疎水性繊維材料の染色法
US5899832A (en) 1996-06-14 1999-05-04 Hougen; Everett D. Compact lung exercising device
DE19720701A1 (de) 1997-05-16 1998-11-19 Gsf Forschungszentrum Umwelt Vorrichtung zur Applikation eines Medikament-Aerosols über die Lunge
US6067984A (en) 1997-10-14 2000-05-30 Piper; Samuel David Pulmonary modulator apparatus
US6102038A (en) 1998-05-15 2000-08-15 Pulmonetic Systems, Inc. Exhalation valve for mechanical ventilator
US6152130A (en) * 1998-06-12 2000-11-28 Microdose Technologies, Inc. Inhalation device with acoustic control
AU1242600A (en) 1998-11-06 2000-05-29 Salter Labs Nebulizer mouthpiece and accessories
US6279574B1 (en) 1998-12-04 2001-08-28 Bunnell, Incorporated Variable flow and pressure ventilation system
US6253766B1 (en) 1999-08-24 2001-07-03 Dhd Healthcare Corporation Continuous positive airway pressure therapy device
US6708690B1 (en) 1999-09-03 2004-03-23 Respironics, Inc. Apparatus and method for providing high frequency variable pressure to a patient
US6581596B1 (en) 1999-09-24 2003-06-24 Respironics, Inc. Apparatus and method of providing high frequency variable pressure to a patient
US6340025B1 (en) 1999-10-04 2002-01-22 American Biosystems, Inc. Airway treatment apparatus with airflow enhancement
US6776159B2 (en) * 1999-11-24 2004-08-17 Dhd Healthcare Corporation Positive expiratory pressure device with bypass
US7059324B2 (en) 1999-11-24 2006-06-13 Smiths Medical Asd, Inc. Positive expiratory pressure device with bypass
US6581598B1 (en) 1999-11-24 2003-06-24 Dhd Healthcare Corporation Positive expiratory pressure device
SE9904382D0 (sv) 1999-12-02 1999-12-02 Siemens Elema Ab High Frequency Oscillation Patient Ventilator System
SE9904645D0 (sv) * 1999-12-17 1999-12-17 Siemens Elema Ab High Frequency Oscillator Ventilator
US6369725B1 (en) 2000-09-26 2002-04-09 International Business Machines Corporation Method for binary to decimal conversion
SE0000206D0 (sv) 2000-01-25 2000-01-25 Siemens Elema Ab High frequency oscillator ventilator
CA2406185C (en) 2000-04-11 2011-03-15 Trudell Medical International Aerosol delivery apparatus with positive expiratory pressure capacity
US6355002B1 (en) 2000-05-22 2002-03-12 Comedica Technologies Incorporated Lung inflection point monitor apparatus and method
US6595203B1 (en) 2000-11-28 2003-07-22 Forrest M. Bird Apparatus for administering intermittent percussive ventilation and unitary breathing head assembly for use therein
US6851425B2 (en) 2001-05-25 2005-02-08 Respironics, Inc. Exhaust port assembly for a pressure support system
DE60226101T2 (de) 2001-06-27 2009-06-25 Fisher & Paykel Healthcare Ltd., East Tamaki Ausatemventil für eine nasale Beatmungsmaske
IL145461A (en) 2001-09-16 2006-09-05 Alyn Woldenberg Family Hospita Breathing and coughing device
US6994083B2 (en) 2001-12-21 2006-02-07 Trudell Medical International Nebulizer apparatus and method
US6705316B2 (en) 2002-03-11 2004-03-16 Battelle Pulmonary Therapeutics, Inc. Pulmonary dosing system and method
WO2004009169A1 (en) 2002-07-22 2004-01-29 Zinder, Oren A respiratory aid apparatus and method
DE10239321B3 (de) * 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US6929007B2 (en) 2003-09-08 2005-08-16 J.H. Emerson Company Insufflation-exsufflation system with percussive assist for removal of broncho-pulmonary secretions
US7191780B2 (en) * 2003-09-22 2007-03-20 Comedica Incorporated Continuous high-frequency oscillation breathing treatment apparatus
JP4685799B2 (ja) * 2004-01-22 2011-05-18 サーモキュア 治療上の低体温を誘導するための呼吸器装置
RU44253U1 (ru) 2004-11-09 2005-03-10 Открытое акционерное общество "Уральский приборостроительный завод" Респиратор высокочастотный
US7448387B2 (en) * 2005-07-26 2008-11-11 Nina Janatpour Tracheostomy tube connector

Also Published As

Publication number Publication date
RU2009140311A (ru) 2011-05-10
US8528547B2 (en) 2013-09-10
CA2682718C (en) 2015-06-23
EP2134397A1 (en) 2009-12-23
AU2008232449B2 (en) 2013-09-12
CN101932354B (zh) 2013-06-19
RU2448742C2 (ru) 2012-04-27
WO2008122045A1 (en) 2008-10-09
NZ580224A (en) 2011-05-27
JP2010523220A (ja) 2010-07-15
CA2682718A1 (en) 2008-10-09
CN101932354A (zh) 2010-12-29
AU2008232449A1 (en) 2008-10-09
BRPI0809602A2 (pt) 2014-11-04
US20080245368A1 (en) 2008-10-09
ZA200906877B (en) 2010-12-29
AU2008232449B8 (en) 2013-09-19
EP2134397A4 (en) 2014-10-22
JP5390504B2 (ja) 2014-01-15

Similar Documents

Publication Publication Date Title
EP2134397B1 (en) High frequency oscillation respiratory therapy device
JP4411165B2 (ja) 連続高周波振動呼吸治療装置
US8025054B2 (en) Passive respiratory therapy device
US8051854B2 (en) Continuous high-frequency oscillation breathing treatment apparatus
EP3218040B1 (en) Respiratory therapy apparatus
EP1908489B1 (en) Vibratory pep therapy system with medicated aerosol nebulizer
EP1078646A2 (en) Continuous positive airway pressure therapy device
JP2007511297A5 (ru)
US20210252236A1 (en) Respiratory therapy devices and assemblies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135927

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140919

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 16/00 20060101AFI20140915BHEP

Ipc: A61M 16/16 20060101ALI20140915BHEP

Ipc: A61M 16/20 20060101ALI20140915BHEP

17Q First examination report despatched

Effective date: 20150901

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CAREFUSION CORPORATION

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1135927

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602008050964

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61M0016000000

Ipc: A61M0016120000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 16/00 20060101ALI20161220BHEP

Ipc: A61M 16/16 20060101ALI20161220BHEP

Ipc: A61M 16/12 20060101AFI20161220BHEP

Ipc: A61M 16/20 20060101ALI20161220BHEP

INTG Intention to grant announced

Effective date: 20170126

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 906159

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008050964

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170705

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 906159

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170705

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171005

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171005

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171006

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171105

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008050964

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

26N No opposition filed

Effective date: 20180406

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008050964

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180430

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180402

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181101

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180402

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180430

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180402

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080402

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705